{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:48:17Z","timestamp":1780681697835,"version":"3.54.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alendronate (ALN) and risedronate (RIS) are bisphosphonates effective in reducing bone loss and fractures associated with postmenopausal osteoporosis. However, it is uncertain how long it takes bone turnover to be re-established after treatment withdrawal, and whether this differs between the two drugs. The objective of this study was to determine the time required to re-establish normal bone turnover after the discontinuation of ALN and RIS treatment in an animal model of estrogen-deficiency osteoporosis. Two hundred ten, 6-mo-old female Sprague-Dawley rats were ovariectomized and 6 wk later were randomized into baseline controls (n = 10) and four treatment groups (n = 50\/group): vehicle-treated controls (CON; 0.3 ml sterile water), ALN (2.4 \u03bcg\/kg), low-dose RIS (RIS low; 1.2 \u03bcg\/kg), and high-dose RIS (RIS high; 2.4 \u03bcg\/kg). Treatments were administered 3 times\/wk by subcutaneous injection. Baseline controls were killed at the initiation of treatment. Other groups were treated for 8 wk, and subgroups (n = 10\/ treatment group) were killed 0, 4, 8, 12, and 16 wk after treatment was withdrawn. Static and dynamic histological analyses were performed for cortical (tibial diaphysis) and trabecular (proximal tibia and L4 vertebrae) bone. DXA and mechanical testing was performed on the L5 vertebra. After 8 wk of treatment, trabecular bone turnover rates were significantly suppressed in all drug-treated animals. Trabecular bone formation rate (BFR\/BS) remained significantly lower than vehicle in bisphosphonate-treated animals through 12 wk. Sixteen weeks after treatment withdrawal, trabecular BFR\/BS in the proximal tibia was re-established in animals treated with RIS but not in animals treated with ALN compared with controls. BMD of the fifth lumbar vertebra remained significantly higher than controls 16 wk after treatment withdrawal in ALN-treated animals but not in RIS-treated animals. Despite reductions in BMD and increases in bone turnover, ultimate force of the fifth lumbar vertebra remained significantly higher in all drug-treated animals through 16 wk after withdrawal.<\/jats:p>","DOI":"10.1359\/jbmr.080501","type":"journal-article","created":{"date-parts":[[2008,5,8]],"date-time":"2008-05-08T11:43:45Z","timestamp":1210247025000},"page":"1689-1697","source":"Crossref","is-referenced-by-count":43,"title":["Recovery of Trabecular and Cortical Bone Turnover After Discontinuation of Risedronate and Alendronate Therapy in Ovariectomized Rats"],"prefix":"10.1093","volume":"23","author":[{"given":"Robyn K","family":"Fuchs","sequence":"first","affiliation":[{"name":"Department of Physical Therapy, Indiana University, Indianapolis, Indiana, USA"},{"name":"Department of Anatomy and Cell Biology, Indiana University Medical School, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J","family":"Phipps","sequence":"additional","affiliation":[{"name":"Procter and Gamble Pharmaceuticals, Mason, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Burr","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA"},{"name":"Department of Anatomy and Cell Biology, Indiana University Medical School, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020319490939600_bib1","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1517\/14656566.7.12.1603","article-title":"Developments in the pharmacotherapeutic management of osteoporosis","volume":"7","author":"Close","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"2024020319490939600_bib2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"2024020319490939600_bib3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1359\/jbmr.1998.13.11.1721","article-title":"Human osteoclast formation and activity in vitro: Effects of alendronate","volume":"13","author":"Breuil","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024020319490939600_bib4","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: Mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J Clin Invest"},{"key":"2024020319490939600_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020319490939600_bib6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/jc.2002-020400","article-title":"Risedronate prevents new vertebral fractures in postmenopausal women at high risk","volume":"88","author":"Watts","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319490939600_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"2024020319490939600_bib8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"2024020319490939600_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomised, placebo-controlled study","volume":"19","author":"Hosking","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"2024020319490939600_bib10","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"2024020319490939600_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"2024020319490939600_bib12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"2024020319490939600_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/edrv.23.1.0453","article-title":"Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint","volume":"23","author":"Marcus","year":"2002","journal-title":"Endocr Rev"},{"key":"2024020319490939600_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S8756-3282(03)00112-1","article-title":"Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal","volume":"33","author":"Bagger","year":"2003","journal-title":"Bone"},{"key":"2024020319490939600_bib15","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024020319490939600_bib16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"key":"2024020319490939600_bib17","first-page":"3109","article-title":"Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group","volume":"85","author":"Tonino","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319490939600_bib18","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319490939600_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(97)00130-7","article-title":"Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women","volume":"103","author":"Stock","year":"1997","journal-title":"Am J Med"},{"key":"2024020319490939600_bib20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.7326\/0003-4819-131-12-199912210-00005","article-title":"Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial","volume":"131","author":"Ravn","year":"1999","journal-title":"Ann Intern Med"},{"key":"2024020319490939600_bib21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"key":"2024020319490939600_bib22","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Longterm Extension (FLEX): A randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"2024020319490939600_bib23","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020319490939600_bib24","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1359\/jbmr.2002.17.12.2237","article-title":"Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats","volume":"17","author":"Cao","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024020319490939600_bib25","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: A potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319490939600_bib26","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"issue":"8 Suppl","key":"2024020319490939600_bib27","first-page":"41","article-title":"Parathyroid hormone as an anabolic therapy for women and men","volume":"28","author":"Bilezikian","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"2024020319490939600_bib28","first-page":"1092","article-title":"Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate","volume":"S27","author":"Delmas","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2024020319490939600_bib29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bone.2006.01.141","article-title":"Bisphosphonate actions: Physical chemistry revisited","volume":"38","author":"Papapoulos","year":"2006","journal-title":"Bone"},{"key":"2024020319490939600_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"2024020319490939600_bib31","first-page":"18","article-title":"Pharmacokinetics of alendronate: An overview","volume":"101","author":"Lin","year":"1999","journal-title":"Int J Clin Pract Suppl"},{"key":"2024020319490939600_bib32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"2024020319490939600_bib33","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"2024020319490939600_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S8756-3282(98)00120-3","article-title":"Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships","volume":"23","author":"van Beek","year":"1998","journal-title":"Bone"},{"key":"2024020319490939600_bib35","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.bone.2005.07.023","article-title":"Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy","volume":"38","author":"Leu","year":"2006","journal-title":"Bone"},{"key":"2024020319490939600_bib36","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","article-title":"Pharmacokinetics\/pharmacodynamics of bisphosphonates: Use for optimisation of intermittent therapy for osteoporosis","volume":"44","author":"Cremers","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2024020319490939600_bib37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-128-4-199802150-00001","article-title":"Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group","volume":"128","author":"McClung","year":"1998","journal-title":"Ann Intern Med"},{"key":"2024020319490939600_bib38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/BF01321840","article-title":"Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats","volume":"53","author":"Wronski","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"2024020319490939600_bib39","first-page":"160","article-title":"Skeletal effects of constant and terminated use of sodium risedronate in ovariectomized rats","volume":"19","author":"Li","year":"1998","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"2024020319490939600_bib40","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.5650100618","article-title":"Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats","volume":"10","author":"Jee","year":"1995","journal-title":"J Bone Miner Res"},{"issue":"4 Suppl","key":"2024020319490939600_bib41","doi-asserted-by":"crossref","first-page":"125S","DOI":"10.1016\/8756-3282(95)00285-L","article-title":"FDA Guidelines and animal models for osteoporosis","volume":"17","author":"Thompson","year":"1995","journal-title":"Bone"},{"key":"2024020319490939600_bib42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S8756-3282(02)00983-3","article-title":"Time course of epiphyseal growth plate fusion in rat tibiae","volume":"32","author":"Martin","year":"2003","journal-title":"Bone"},{"key":"2024020319490939600_bib43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/BF02012553","article-title":"Rate of normal longitudinal bone growth in the rat","volume":"10","author":"Hansson","year":"1972","journal-title":"Calcif Tissue Res"},{"key":"2024020319490939600_bib44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/8756-3282(94)90272-0","article-title":"Effects of prostaglandin E2 and risedronate administration on cancellous bone in older female rats","volume":"15","author":"Lin","year":"1994","journal-title":"Bone"},{"key":"2024020319490939600_bib45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s007740050058","article-title":"Skeletal effects of constant and terminated use of risedronate on cortical bone in ovariectomized rats","volume":"17","author":"Li","year":"1999","journal-title":"J Bone Miner Metab"},{"key":"2024020319490939600_bib46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00774-005-0612-9","article-title":"Effects of combined calcitonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats","volume":"23","author":"Ogawa","year":"2005","journal-title":"J Bone Miner Metab"},{"key":"2024020319490939600_bib47","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2174\/1381612023393585","article-title":"Bisphosphonates as a foundation of drug delivery to bone","volume":"8","author":"Uludag","year":"2002","journal-title":"Curr Pharm Des"},{"key":"2024020319490939600_bib48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"key":"2024020319490939600_bib49","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.bone.2007.07.005","article-title":"Risedronate did not block the maximal anabolic effect of PTH in aged rats","volume":"41","author":"Yao","year":"2007","journal-title":"Bone"},{"key":"2024020319490939600_bib50","first-page":"473","article-title":"Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats","volume":"20","author":"Lin","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"2024020319490939600_bib51","first-page":"926","article-title":"Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals","volume":"19","author":"Lin","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"2024020319490939600_bib52","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int"},{"key":"2024020319490939600_bib53","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"2024020319490939600_bib54","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024020319490939600_bib55","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1365-2125.1999.00035.x","article-title":"The effect of dosing regimen on the pharmacokinetics of risedronate","volume":"48","author":"Mitchell","year":"1999","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.080501","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/23\/10\/1689\/56570766\/5650231019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/23\/10\/1689\/56570766\/5650231019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T23:44:54Z","timestamp":1738194294000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/23\/10\/1689-1697\/7599501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,1]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2008,10,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.080501","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1157357.617507","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,10,1]]},"published":{"date-parts":[[2008,10,1]]}}}